About Us
The Why: Making Humanity's Century-Long, Healthy Lifespan a Reality
The world’s population is aging at an unprecedented rate. By 2030, one in six people worldwide will be 60 or older. By 2050, the global population aged 60 and over will have doubled to 2.1 billion. Meanwhile, the number of people aged 80 and over is projected to triple between 2020 and 2050, reaching 426 million (source: World Health Organization). Yet aging brings a cascade of debilitating conditions (e.g. sarcopenia, frailty, dementia, and metabolic disorders) that compromise quality of life and independence.
At Biophytis, we envision a future where people don’t just live longer – but longer healthier.
Executive Committee
Board of Directors
Scientific Advisory Board
Executive Committee
Board of Directors
Our Strategic Programs: A Comprehensive Approach
Our Longevity Research Platform
We explore and identify the fundamental mechanisms of aging through a unique platform that combines synergistic technology modalities systematically accelerated by AI through our partnership with Lynx Analytics. This enables us to discover therapeutic solutions across the aging disease spectrum.
BIO101 in Sarcopenia
Sarcopenia is a progressive, generalized loss of skeletal muscle mass and strength affecting up to 1 in 4 people over 60. With no approved treatments available, BIO101 represents the most advanced drug candidate in development. Our Phase 2 trial demonstrated significant improvements in mobility, and we’re now preparing for the first-ever Phase 3 study in sarcopenia.
BIO101 in Obesity
With obesity affecting 1 billion patients globally and 96% experiencing mobility issues, there’s an urgent need to preserve muscle function during weight loss. BIO101 is being developed as a combination treatment to GLP-1 receptor agonists, addressing the critical challenge of muscle mass loss during obesity management.
